1	Self-reported and physiological reactions to the third BNT162b2 mRNA
2	COVID-19 (booster) vaccine dose
3	Running title: Reactions to the third Pfizer COVID-19 (booster) vaccine dose
4	Merav Mofaz, MSc ¹ , Matan Yechezkel, MSc ¹ , Grace Guan, MSc ² , Margaret L. Brandeau, PhD ² , Tal Patalon, MD ³ ,
5	Sivan Gazit, MD ³ , Dan Yamin, PhD ^{1,4,+} , and Erez Shmueli, PhD ^{1,5,+,*}
6	¹ Department of Industrial Engineering, Tel Aviv University, Tel Aviv, Israel.
7	² Department of Management Science and Engineering, Stanford University, Stanford CA, USA.
8	³ Kahn Sagol Maccabi (KSM) Research & Innovation Center, Maccabi Healthcare Services, Tel Aviv, Israel.
9	⁴ Center for Combatting Pandemics, Tel Aviv University, Tel Aviv, Israel.
10	⁵ MIT Media Lab, Cambridge MA, USA.
11	⁺ Equal contribution
12	*Corresponding author. Email: shmueli@tau.ac.il

13 Keywords: COVID-19 vaccine, third COVID-19 dose, booster vaccine, BNT162b2, adverse effects, wearables

14 Abstract

15 **Background**: The rapid rise in hospitalizations associated with the Delta-driven COVID-19 16 resurgence, and the imminent risk of hospital overcrowding, led the Israeli government to 17 initialize a national third (booster) COVID-19 vaccination campaign in early August 2021, offering the BNT162b2 mRNA vaccine to individuals who received their second dose over five 18 19 months ago. However, the safety of the third (booster) dose has not been fully established yet. Objective: Evaluate the short-term, self-reported and physiological reactions to the third 20 21 BNT162b2 mRNA COVID-19 (booster) vaccine dose. 22 **Design**: A prospective observational study, in which participants are equipped with a smartwatch 23 and fill in a daily questionnaire via a dedicated mobile application for a period of 21 days, 24 starting seven days before the vaccination. 25 Setting: An Israel-wide third (booster) vaccination campaign. Participants: A group of 1503 (18+ years of age) recipients of at least one dose of the 26 BNT162b2 vaccine between December 20, 2020, and September 6, 2021, out of a larger cohort 27 28 of 2,848 prospective study participants. 1,231 of the participants were recipients of the third 29 vaccine dose. 30 Measurements: Daily self-reported questionnaires regarding local and systemic reactions, mood level, stress level, sport duration, and sleep quality. Heart rate and heart rate variability were 31

32 continuously measured by Garmin Vivosmart 4 smartwatches.

Results: Local and systemic reactions reported following the third (booster) dose administration are similar to those reported following the second dose and considerably greater than those reported following the first dose. Our analyses of self-reported well-being indicators as well as the objective heart rate and heart rate variability measures recorded by the smartwatches further

support this finding. These measures returned to their baseline levels within three days from
inoculation with the third dose. These trends were consistent regardless of age, gender or the
existence of an underlying medical condition.

40 Limitations: Participants may not adequately represent the vaccinated population in Israel and
41 elsewhere.

42 **Conclusion**: Our work further supports the safety of a third COVID-19 BNT162b2 mRNA

43 (booster) vaccine dose from both a subjective and an objective perspective.

44 **Primary funding source**: European Research Council (ERC) project #949850.

45

46 **Introduction:**

The SARS-CoV-2 Delta variant (also termed variant B.1.617.2) was discovered in October 2020, 47 in India, and was designated as a variant of concern by the World Health Organization (WHO) in 48 May 2021 (1–3). Since its discovery, it has spread worldwide and has rapidly become the most 49 50 dominant variant in many countries (4–7). Although the BNT162b2 COVID-19 vaccine is highly 51 effective against the Alpha variant (8), recent studies show that the effectiveness of the Pfizer-52 BioNTech vaccines is notably lower against the Delta variant -88% compared to 93.7% against 53 the Alpha variant (9–12). Moreover, recent evidence shows that fully vaccinated individuals infected with the virus can easily transmit it further, as their peak viral burden is similar to that 54 observed in unvaccinated individuals (7,10). In Israel, the Delta variant has accelerated COVID-55 56 19 infection and hospitalization, with numbers doubling every ten days between July 1, 2021 and August 9, 2021 (7,13), despite the high coverage of the BNT162b2 vaccine in Israel during this 57 period—greater than 75% coverage with two Pfizer doses in the eligible population (individuals 58 \geq 12 years of age) (13). 59

60

61 The rapid rise in hospitalizations associated with the Delta-driven COVID-19 resurgence, and 62 the imminent risk of hospital overcrowding, led the Israeli government to initialize on July 30, 63 2021, an unparalleled, pro-active, national third (booster) vaccine shot campaign, offering the BNT162b2 mRNA COVID-19 vaccine to individuals over the age of 60. On August 13, 2021, 64 65 the booster campaign was expanded to include those over 50 years of age, reaching 63% thirddose coverage among the eligible population within only 26 days (7,14–16). Two weeks later, on 66 August 29, 2021, the campaign was expanded to the general population, demanding only that 67 68 five months have passed since receipt of the second dose, reaching 40% third-dose coverage 69 among the eligible population under the age of 50, within 16 days (13,17).

70

Currently, limited information is available on the safety of a BNT162b2 third dose (18,19), with such a booster vaccine yet to be authorized by the US Food and Drug Administration (FDA) to the general population (20). While recent evidence shows that a third BNT162b2 dose in immunocompromised individuals has a favorable safety profile (19,21), a formal clinical trial for assessing the safety of a third (booster) dose in the general population has not yet been fully established.

77

Here, we evaluate the short-term effects of a third BNT162b2 mRNA COVID-19 vaccine dose on self-reported and physiological indicators. We followed a cohort of 2,848 participants; of these, 1,503 participants received at least one dose of the BNT162b2 vaccine after joining the study. Each participant received a dedicated mobile application and a Garmin Vivosmart 4

82 smartwatch. The mobile application collected daily self-reported questionnaires on local and 83 systemic reactions as well as various well-being indicators. The smartwatch continuously 84 monitored several physiological measures, including heart rate and heart rate variability (HRV). 85 Our analysis of the comprehensive data on each participant examines the safety of a third 86 (booster) vaccine dose from both a subjective perspective (patient questionnaire) and an 87 objective perspective (smartwatch data).

88

89 Materials and Methods

90 Study design and participants

Our study includes a prospective cohort of 2,848 participants (18+ years of age) who were recruited between November 1, 2020 and September 6, 2021. The 1,503 participants who reported receipt of at least one of the three BNT162b2 mRNA COVID-19 vaccine shots after joining the study served as the base cohort for our analysis. Specifically, of these 1,503 participants, during the study, 223 received their first dose, 351 their second dose, and 1,231 their third dose.

97

We employed a professional survey company to recruit participants and ensure they follow through with the study requirements. Participant recruitment was performed via advertisements on social media and word-of-mouth. Each participant provided informed consent by signing a form after receiving a comprehensive explanation on the study. Then, participants completed a one-time enrollment questionnaire, were equipped with Garmin Vivosmart 4 smartwatches, and installed two applications on their mobile phones: (1) the PerMed application (22) that collected daily self-reported questionnaires, and (2) an application that passively recorded the smartwatch

105 data. Participants were asked to wear their smartwatches as much as possible. The survey 106 company ensured that participants' questionnaires were completed daily, that their smartwatches 107 were charged and properly worn, and that any technical problems with the mobile applications or 108 smartwatch were resolved.

109

110 **PerMed mobile application**

Participants used the PerMed mobile application (22) to fill out daily questionnaires. The questionnaire allowed participants to report various well-being indicators, including mood level (on a scale of 1 [awful] to 5 [excellent]), stress level (on a scale of 1 [very low] to 5 [very high]), sport duration (in minutes), and sleep quality (on a scale of 1 [awful] to 5 [excellent]). The questionnaire also collected data on clinical symptoms consistent with the local and systemic reactions observed in the BNT162b2 mRNA Covid-19 clinical trial (23), with an option to add other symptoms as free text. (For more details see Appendix A in the Supplemental Material)

118

We implemented preventive measures to improve the quality, continuity, and reliability of the collected data. Each day, if by 7 pm, participants had not yet filled out the daily questionnaire, they received a reminder notification through the PerMed application. Furthermore, we used a dedicated dashboard to identify participants who continually neglected to complete the daily questionnaires; these participants were contacted by the survey company and were encouraged to better adhere to the study protocol.

125

126 The smartwatch

Participants were equipped with Garmin Vivosmart 4 smart fitness trackers. Among other
features, the smartwatch provides all-day heart rate and heart rate variability tracking capabilities
(24).

130

The optical wrist heart rate (HR) monitor of the smartwatch is designed to continuously monitor a user's heart rate. The frequency at which heart rate is measured varies and may depend on the level of activity of the user: when the user starts an activity, the optical HR monitor's measurement frequency increases. Examining the data collected in our study, we identified an HR sample roughly every 15 seconds.

136

Since heart rate variability (HRV) is not easily accessible through Garmin's application programming interface (API), we use Garmin's stress level instead, which is calculated based on HRV. Specifically, the device uses heart rate data to determine the interval between each heartbeat. The variable length of time between each heartbeat is regulated by the body's autonomic nervous system. Less variability between beats correlates with higher stress levels, whereas an increase in variability indicates less stress (25). A similar relationship between HRV and stress was also seen in (26,27).

144

While the Garmin smartwatch provides state-of-the-art wrist monitoring, it is not a medicalgrade device, and some readings may be inaccurate under certain circumstances, depending on factors such as the fit of the device and the type and intensity of the activity undertaken by a participant (28–30).

150 Statistical analysis

Questionnaire data were preprocessed by manually categorizing any self-reported symptom entered as free text. In addition, if participants filled out the questionnaire more than once in one day, the last entry from that day was used in the analysis. Smartwatch data were preprocessed as follows. First, we computed the mean value of each hour of data. We then performed linear interpolation to impute missing hourly means. Lastly, we smoothed the data by calculating the five-hour moving average.

157

For each participant, we defined the 7-day period prior to vaccination as the baseline period. We noted any pre-existing clinical symptoms from the last questionnaire completed during the baseline period. Next, we calculated the percentage of participants who reported new (that is, not pre-existing) local or systemic reactions in the 48 hours after vaccination. For each reaction, we used a beta distribution to determine a 90% confidence interval.

163

We also calculated the mean difference in well-being indicators between the post-vaccination period and the baseline period. Specifically, for each indicator, for each of the three days postvaccination and for each participant, we calculated the difference between that indicator's value and its corresponding value in the baseline period. Then, we calculated the mean value over all participants and the associated 90% confidence interval.

169

To compare the changes in smartwatch physiological indicators over the seven days (168 hours) post vaccination with those of the baseline period, we performed the following steps. First, for each participant and each hour during the seven days post vaccination, we calculated the

173	difference between that hour's indicator value and that of the corresponding hour in the baseline
174	period (keeping the same day of the week and same hour during the day). Then, we aggregated
175	each hour's differences over all participants to calculate a mean difference and associated 90%
176	confidence interval, which is analogous to a one-sided t-test with significance level 0.05.
177	
178	We repeated the above analyses for the third dose stratified by age groups (\geq 50 vs. <50), gender
179	(males vs. females) and the existence of an underlying medical condition (present vs. not
180	present) from the list specified in Table 1.
181	
182	Ethical Approval
183	Before participating in the study, all subjects were advised, both orally and in writing, as to the
184	nature of the study and gave written informed consent. The study was approved by MHS'
185	Helsinki institutional review board, protocol number 0122-20-MHS.
186	
187	Results
188	Of the 1,503 participants who received at least one dose of the BNT162b2 vaccine after joining
189	the study, 796 (52.96%) were women, and 707 (47.04%) were men. Their age ranged between 19
190	and 88 years, with a median age of 53 (Table 1). 1,173 (78.04%) participants had a body mass
191	index below 30, and 404 (26.88%) had at least one specific underlying medical condition (Table
192	1). The distributions of age and gender and the existence of underlying medical conditions were
193	relatively invariable across the recipients of the first, second and third dose (Table 1).
194	

Table 1. Characteristics of the participants

Characteristic	All Participants	First Dose	Second Dose	Third Dose
	(N=1,503)	(N=223)	(N=351)	(N=1,231)
Gender				
Male	47.04% (707)	45.29% (101)	45.58% (160)	47.93% (590)
Female	52.96% (796)	54.71% (122)	54.42% (191)	52.07% (641)
Age group				
18-29 yr	12.51% (188)	6.28% (14)	11.11% (39)	11.86% (146)
30-39 yr	15.9% (239)	4.93% (11)	15.1% (53)	15.11% (186)
40-49 yr	10.98% (165)	6.73% (15)	11.97% (42)	10.24% (126)
50-59 yr	26.95% (405)	28.7% (64)	24.79% (87)	28.92% (356)
60-69 yr	23.62% (355)	31.39% (70)	21.37% (75)	24.7% (304)
≥ 70 yr	10.05% (151)	21.97% (49)	15.67% (55)	9.18% (113)
Body-mass index*				
< 30.0	78.04% (1,173)	78.48% (175)	79.77% (280)	77.42% (953)
≥ 30.0	20.56% (309)	18.39% (41)	17.09% (60)	21.61% (266)
Unspecified	1.4% (21)	3.14% (7)	3.13% (11)	0.97% (12)
Underlying Medical Cond	lition			
Hypertension	15.04% (226)	20.63% (46)	15.95% (56)	15.52% (191)
Diabetes	9.12% (137)	13% (29)	7.98% (28)	8.94% (110)
Heart disease	5.06% (76)	7.17% (16)	4.56% (16)	5.36% (66)
Chronic lung disease	5.06% (76)	4.93% (11)	3.7% (13)	5.28% (65)
Immune suppression	0.86% (13)	1.35% (3)	0.85% (3)	0.97% (12)
Cancer	0.6% (9)	0.45% (1)	0.57% (2)	0.65% (8)
Renal failure	0.53% (8)	1.79% (4)	1.42% (5)	0.49% (6)
None of the above	71.99% (1,082)	64.57% (144)	72.08% (253)	71.57% (881)

Unspecified	1.13% (17)	1.35% (3)	2.85% (10)	0.57% (7)
-------------	------------	-----------	------------	-----------

* The body-mass index is the weight in kilograms divided by the square of the height in meters

195

196 Our examination of the self-reported local and systemic reactions revealed that the reactions reported following the third vaccine dose are very similar to those reported following the second 197 dose, and considerably greater than those observed following the first dose (Figure 1). 198 Specifically, 65.4% (9 % CI: 62.8-67.8% of the participants did not report any new symptoms 199 after receiving the third dose, compared to 87.7% (9 % CI: 83.2-91.0% and 66.2% (9 % CI: 200 61.7-70.3% after the first and second doses, respectively. Moreover, the most frequently 201 reported types of reactions-fatigue, headache, muscle pain, fever, and chills-were similar after 202 the second and third doses. These reactions faded in nearly all participants within three days 203 204 (Figure S10 in the Supplemental Material). Notably, these trends are consistent with those 205 reported in the first and second dose BNT162b2 mRNA vaccine clinical trial (23).






Figure 1. Local and systemic reactions reported by participants through the mobile application. The
bars represent the percentage of participants who reported a given symptom. Error bars represent 90%
confidence intervals.

211

For the self-reported well-being indicators (Fig. 2), we found that during the first two days after the third vaccine dose, participants exhibited a significant reduction in mood level (Fig. 2A), sport duration (Fig. 2C), sleep quality (Fig. 2D) and a notable increase in stress level (Fig. 2B) compared to baseline levels. These changes faded away on the third day post vaccination. A similar trend can be observed after the second vaccine dose, with the exception of reported stress level that remains below the baseline level during the second and third days post-vaccination.




Figure 2. Changes in subjective well-being indicators reported by participants through the mobile application. Mean difference compared to baseline levels for the well-being indicators of (A) Mood level, (B) Stress level, (C) Sport duration, and (D) Sleep quality. Mood level, Stress level, and Sleep

quality were reported on a 1-5 Likert scale. Sport duration was measured in minutes. Error bars represent
90% confidence intervals. Horizontal dashed lines represent no change compared to baseline levels.

224

We observed similar trends when analyzing the objective continuous physiological measurements collected by the smartwatch (Fig. 3). Specifically, we identified a considerable rise in both the heart rate and the heart rate variability-based stress indicators in the first 48 hours following the administration of the third dose. Measurements returned to their baseline levels within 72 hours. The trends observed for the objective indicators were consistent with those of the subjective indicators also in the following sense - similar changes following the second and third doses, and greater changes following the second and third doses compared to the first dose.






Figure 3. Changes in objective physiological indicators measured through the smartwatch. Mean difference in smartwatch-recorded (A-C) heart rate and in (D-F) heart rate variability-based stress indicators following the first, second and third dose, compared to their baseline levels. Mean values are depicted as solid lines; 90% confidence intervals are presented as shaded regions. The horizontal dashed line represents no change compared to the baseline levels, and vertical lines represent 24-hour periods.

239

We also stratified our analyses of well-being and smartwatch physiological indicators after the 240 third vaccination by age group, gender, and existence of a prior underlying medical condition. 241 242 For all stratifications, trends were similar to those observed in the general population. Namely, there were considerable changes in the two days after vaccine administration that faded almost 243 entirely after three days (Figures S1-S9 in the Supplemental Material). We also found that 244 245 participants 50 years of age or older exhibited milder reactions than those below 50 years of age 246 (Figures S1, S4 and S7 in the Supplemental Material); male participants exhibited milder reactions than female participants (Figures S2 and S8 in the Supplemental Material); and 247 participants with an underlying medical condition experienced milder reactions compared to 248 those without an underlying medical condition (Figures S3, S6 and S9 in the Supplemental 249 250 Material).

251

252 **Discussion**

Our key findings suggest that local and systemic reactions reported following the third (booster) vaccine dose administration are very similar to those reported following the second dose and considerably greater than those observed following the first dose. Our analyses of both selfreported well-being indicators and objective smartwatch physiological indicators underscore these results. Furthermore, within three days from inoculation with the third dose, all measures returned to their baseline levels in nearly all participants.

259

We identified differences in subpopulations based on gender, age and underlying medical condition following administration of the third vaccine dose. It has been previously suggested

262 that reactions caused by the COVID-19 vaccine are a byproduct of a short burst of IFN-I 263 generation concomitant with induction of an effective immune response (31). IFN-I generation is 264 substantially stronger in females than in males and stronger in younger and healthier individuals 265 than in older and less healthy ones. We found that participants below the age of 65, females, and those without an underlying medical condition experienced greater reactions both in self-266 reported local and systemic reactions and well-being indicators as well as in objective 267 physiological measurements recorded by the smartwatch. Our results are also in line with a 268 269 previous study that found similar trends after the first and second doses (32).

270

Clinical trials have not yet capitalized on the comprehensive physiological measures generated by wearables. Currently, the FDA and European Medicines Agency (EMA) evaluate the safety and create guidelines for newly developed vaccines primarily based on subjective, self-reported questionnaires (33,34). Much of the scientific literature discusses these self-reported side effects of COVID-19 vaccines. However, integrating wearables into clinical trials, alongside selfreported questionnaires, can provide more precise and rich data regarding the vaccines' effects on physiological measures.

278

Our study has several limitations. First, the 1,503 individuals who comprise the base cohort of our analyses may not be representative of the vaccinated population in Israel or globally. Nevertheless, the changes observed in self-reported reactions and well-being indicators as well as objective physiological indicators recorded by the smartwatches were statistically significant and consistent with each other. Moreover, the reaction types, frequency and duration we observed for the first and second dose were similar to those observed in the BNT162b2 mRNA

vaccine clinical trials (23). In addition, a clear pattern of returning to baseline levels was observed within 72 hours post inoculation in all examined measures. Lastly, although the sample size was limited, trends were consistent regardless of age group, gender, and the existence of underlying medical conditions.

289

Second, we did not explicitly control for the effects of the observational trial setting (i.e., participating in a trial, wearing a smartwatch, potential concerns regarding the vaccine, etc.). Any effects of the observational trial setting should, in principle, have similar impacts on our analysis of each of the three vaccine doses. However, since we found no deviations in most measurements from baseline levels in the subset of participants who received their first dose, we believe the changes observed after the second and third doses arise from an actual reaction to the vaccine.

297

Third, the smartwatches used to obtain physiological measurements are not medical-grade devices. Nevertheless, recent studies show a considerably accurate heart rate measurement in the previous versions of the smartwatch used in this study (28,29). Moreover, our analysis focused on the change in measurements compared to their baseline values rather than on their absolute values.

303

Finally, the only vaccine available in Israel is the BNT162b2 mRNA vaccine. Although our findings may not directly generalize to other types of COVID-19 vaccines, we believe that applying our analyses on other vaccines are likely to yield qualitatively similar findings, due to the similarities observed between different COVID-19 vaccines (23,35,36).

308

309 Our study strengthens the evidence regarding the short-term safety of the booster BNT162b2 vaccine in several ways. First, reports of local and systemic reactions following the third dose 310 311 were very similar to those observed following the second dose, which was already shown in clinical trials to be safe (23). Second, the considerable changes observed in all indicators during 312 the first two days after receiving the third vaccine, including self-reported local and systemic 313 314 reactions and well-being indicators as well as objective physiological indicators collected by the 315 smartwatch, returned to their baseline levels. Third, regardless of the observed differences 316 between subpopulations, our analyses indicate a clear pattern of return to baseline levels in all considered subpopulations. 317

318

In conclusion, our study supports the short-term safety of the third BNT162b2 mRNA COVID-19 (booster) vaccine dose and mitigates, in part, concerns regarding its short-term effects. The medical and scientific communities could greatly benefit from the largely unbiased data generated by digital health technologies such as the wearable data which we analyzed in this study. Our findings could also be of interest to public health officials and other stakeholders, as it is important that objective measures are given attention in the critical evaluation of clinical trials.

325 **References**

326	1.	Kupferschmidt K, Wadman M. Delta variant triggers new phase in the pandemic. Science
327		(80-) [Internet]. 2021 Jun 25 [cited 2021 Aug 22];372(6549):1375–6. Available from:
328		https://science.sciencemag.org/content/372/6549/1375
329	2.	Tracking SARS-CoV-2 variants [Internet]. [cited 2021 Aug 22]. Available from:
330		https://www.who.int/en/activities/tracking-SARS-CoV-2-variants
331	3.	Mlcochova P, Kemp S, Dhar MS, Papa G, Meng B, Mishra S, et al. SARS-CoV-2
332		B.1.617.2 Delta variant replication, sensitivity to neutralising antibodies and vaccine
333		breakthrough. bioRxiv [Internet]. 2021 Aug 6 [cited 2021 Aug 22];2021.05.08.443253.
334		Available from: https://www.biorxiv.org/content/10.1101/2021.05.08.443253v5
335	4.	Delta Variant: What We Know About the Science CDC [Internet]. [cited 2021 Aug 22].
336		Available from: https://www.cdc.gov/coronavirus/2019-ncov/variants/delta-variant.html
337	5.	Mahase E. Delta variant: What is happening with transmission, hospital admissions, and
338		restrictions? BMJ [Internet]. 2021 Jun 15 [cited 2021 Aug 22];373:n1513. Available from:
339		https://www.bmj.com/content/373/bmj.n1513
340	6.	Weekly epidemiological update on COVID-19 - 17 August 2021 [Internet]. [cited 2021
341		Aug 22]. Available from: https://www.who.int/publications/m/item/weekly-
342		epidemiological-update-on-covid-1917-august-2021
343	7.	Wadman M. Israel's grim warning: Delta can overwhelm shots. Science (80-) [Internet].
344		2021 Aug 20 [cited 2021 Aug 22];373(6557):838–9. Available from:
345		https://science.sciencemag.org/content/373/6557/838

346	8.	Munitz A,	Yechezkel M	, Dickstein Y	, Yamin D	, Gerlic M.	BNT162b2	vaccination

- 347 effectively prevents the rapid rise of SARS-CoV-2 variant B.1.1.7 in high-risk populations
- in Israel. Cell Reports Med [Internet]. 2021 Apr [cited 2021 May 3];0(0):100264.
- Available from: https://linkinghub.elsevier.com/retrieve/pii/S266637912100080X
- 350 9. Bernal JL, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al.
- Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant.
- 352 https://doi.org/101056/NEJMoa2108891 [Internet]. 2021 Jul 21 [cited 2021 Aug
- 353 22];385(7):585–94. Available from:
- 354 https://www.nejm.org/doi/full/10.1056/NEJMoa2108891
- 35510.Pouwels KB, Pritchard E, Matthews PC, Stoesser N, Eyre DW, Vihta K-D, et al. Impact
- of Delta on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in
 the UK.
- 11. Sheikh A, McMenamin J, Taylor B, Robertson C. SARS-CoV-2 Delta VOC in Scotland:
- demographics, risk of hospital admission, and vaccine effectiveness. Lancet [Internet].

360 2021 Jun 26 [cited 2021 Aug 22];397(10293):2461–2. Available from:

- 361 http://www.thelancet.com/article/S0140673621013581/fulltext
- 12. Nasreen S, He Msc S, Mph HC, Brown Phd KA, Gubbay JB, Buchan SA, et al.
- Effectiveness of COVID-19 vaccines against variants of concern, Canada on behalf of the
- 364 Canadian Immunization Research Network (CIRN) Provincial Collaborative Network
- 365 (PCN) Investigators. [cited 2021 Aug 22]; Available from:
- 366 https://doi.org/10.1101/2021.06.28.21259420
- 13. COVID-19 Datasets- Government Data [Internet]. [cited 2020 May 30]. Available from:

368 https://data.gov.il/dataset/covid-19

369	14.	The Ministry of Health Director General Has Approved the Recommendation to
370		Administer a Third Vaccine Doe to 50-Year-Olds and Older and to Other Populations
371		Ministry of Health [Internet]. [cited 2021 Aug 22]. Available from:
372		https://www.gov.il/en/departments/news/13082021-01
373	15.	The Vaccination Advisory Committee Presented Data and Recommended the
374		Administration of a Third Dose to Older Adults Ministry of Health [Internet]. [cited 2021
375		Aug 22]. Available from: https://www.gov.il/en/departments/news/29072021-04
376	16.	Statement by PM Bennett on Third Dose of the COVID Vaccine to Israeli Citizens over
377		the Age of 60 Prime Minister's Office [Internet]. [cited 2021 Aug 22]. Available from:
378		https://www.gov.il/en/Departments/news/event_press290721
379	17.	The Vaccination Policy and the New Green Pass that will Take Effect Soon Ministry of
380		Health [Internet]. [cited 2021 Sep 15]. Available from:
381		https://www.gov.il/en/departments/news/29082021-01
382	18.	Joint Statement from HHS Public Health and Medical Experts on COVID-19 Booster
383		Shots CDC Online Newsroom CDC [Internet]. [cited 2021 Aug 22]. Available from:
384		https://www.cdc.gov/media/releases/2021/s0818-covid-19-booster-shots.html
385	19.	COVID-19 Vaccines for Moderately to Severely Immunocompromised People CDC
386		[Internet]. [cited 2021 Aug 22]. Available from: https://www.cdc.gov/coronavirus/2019-
387		ncov/vaccines/recommendations/immuno.html

388 20. Joint Statement from HHS Public Health and Medical Experts on COVID-19 Booster

389 Shots FDA [Internet]. [cited 2021 A	ug 23]. Available f	from: https://www.fda.gov/news-
---	---------------------	---------------------------------

- 390 events/press-announcements/joint-statement-hhs-public-health-and-medical-experts-
- 391 covid-19-booster-shots
- 392 21. Kamar N, Abravanel F, Marion O, Couat C, Izopet J, Bello A Del. Three Doses of an
- 393 mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients.
- 394 https://doi.org/101056/NEJMc2108861 [Internet]. 2021 Jun 23 [cited 2021 Aug
- 23];385(7):661–2. Available from: https://www.nejm.org/doi/10.1056/NEJMc2108861
- 396 22. Oved S, Mofaz M, Lan A, Einat H, Kronfeld-Schor N, Yamin D, et al. Differential effects
- of COVID-19 lockdowns on well-being: interaction between age, gender and chronotype
- 398 [Internet]. 2021 Jan [cited 2021 Mar 31]. Available from:
- 399 https://www.researchsquare.com
- 400 23. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and
- 401 Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med [Internet]. 2020 Dec
- 402 31 [cited 2021 Mar 31];383(27):2603–15. Available from:
- 403 http://www.nejm.org/doi/10.1056/NEJMoa2034577
- 404 24. VÍVOSMART ® 4 Owner's Manual. 2018 [cited 2021 Aug 23]; Available from:
 405 www.garmin.com
- 406 25. What Is the Stress Level Feature on My Garmin Watch? | Garmin Support [Internet].
- 407 [cited 2021 Aug 24]. Available from: https://support.garmin.com/en-
- 408 US/?faq=WT9BmhjacO4ZpxbCc0EKn9
- 409 26. Kim H-G, Cheon E-J, Bai D-S, Lee YH, Koo B-H. Stress and Heart Rate Variability: A
- 410 Meta-Analysis and Review of the Literature. Psychiatry Investig [Internet]. 2018 Mar 1

411		[cited 2021 Aug 24];15(3):235. Available from: /pmc/articles/PMC5900369/
412	27.	Pereira T, Almeida PR, Cunha JPS, Aguiar A. Heart rate variability metrics for fine-
413		grained stress level assessment. Comput Methods Programs Biomed. 2017 Sep 1;148:71-
414		80.
415	28.	RK R, R P, DP Z, B S, J EY, E D, et al. Accuracy of Wrist-Worn Activity Monitors
416		During Common Daily Physical Activities and Types of Structured Exercise: Evaluation
417		Study. JMIR mHealth uHealth [Internet]. 2018 Dec 1 [cited 2021 Aug 23];6(12).
418		Available from: https://pubmed.ncbi.nlm.nih.gov/30530451/
419	29.	Bent B, Goldstein BA, Kibbe WA, Dunn JP. Investigating sources of inaccuracy in
420		wearable optical heart rate sensors. npj Digit Med 2020 31 [Internet]. 2020 Feb 10 [cited
421		2021 Aug 23];3(1):1–9. Available from: https://www.nature.com/articles/s41746-020-
422		0226-6
423	30.	Accuracy Garmin [Internet]. [cited 2021 Aug 22]. Available from:
424		https://www.garmin.com/en-US/legal/atdisclaimer/
425	31.	
	51.	Bunders MJ, Altfeld M. Implications of Sex Differences in Immunity for SARS-CoV-2
426	51.	Bunders MJ, Altfeld M. Implications of Sex Differences in Immunity for SARS-CoV-2 Pathogenesis and Design of Therapeutic Interventions. Immunity. 2020 Sep 15;53(3):487–
426 427	51.	
	32.	Pathogenesis and Design of Therapeutic Interventions. Immunity. 2020 Sep 15;53(3):487–
427		Pathogenesis and Design of Therapeutic Interventions. Immunity. 2020 Sep 15;53(3):487– 95.
427 428		 Pathogenesis and Design of Therapeutic Interventions. Immunity. 2020 Sep 15;53(3):487–95. Menni C, Klaser K, May A, Polidori L, Capdevila J, Louca P, et al. Vaccine side-effects
427 428 429		 Pathogenesis and Design of Therapeutic Interventions. Immunity. 2020 Sep 15;53(3):487–95. Menni C, Klaser K, May A, Polidori L, Capdevila J, Louca P, et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app

433	33.	Development and	Licensure of	Vaccines to	Prevent	COVID-19	FDA	[Internet]	.[cited

- 434 2021 Mar 31]. Available from: https://www.fda.gov/regulatory-information/search-fda-
- 435 guidance-documents/development-and-licensure-vaccines-prevent-covid-19
- 436 34. Clinical trials in human medicines | European Medicines Agency [Internet]. [cited 2021
- 437 Aug 23]. Available from: https://www.ema.europa.eu/en/human-regulatory/research-
- 438 development/clinical-trials-human-medicines
- 439 35. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety
- 440 of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med [Internet]. 2021 Feb 4 [cited
- 441 2021 Mar 31];384(5):403–16. Available from:
- 442 http://www.nejm.org/doi/10.1056/NEJMoa2035389
- 443 36. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety
- and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an
- interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.
- 446 Lancet [Internet]. 2021 Jan 9 [cited 2021 Mar 31];397(10269):99–111. Available from:
- 447 https://doi.org/10.1016/

Financial Support 449

450	This research was supported by the European Research Council (ERC) project #949850 and the
451	Israel Science Foundation (ISF), grant No. 3409/19, within the Israel Precision Medicine
452	Partnership program. MLB and GG received support from the Koret foundation grant for
453	Smart Cities and Digital Living 2030.
454	
455	Data availability
456	Researchers interested in obtaining an aggregated version of the data sufficient to reproduce the
457	results reported in this paper should contact the corresponding author.
458	
459	Authors' contributions
460	Conception and design: DY, ES. Collection and assembly of data: MM, TP, SG, ES. Analysis
461	and interpretation of the data: MM, GG, MLB, DY, ES. Statistical expertise: MM, DY, ES.
462	Drafting the article: MM, MY, DY, ES. Critical revision of the article for important intellectual
463	content: DY, ES. Final approval of the article: All authors. Obtaining funding: DY, ES.
464	
465	Disclosures
466	All authors have disclosed no conflicts of interest.
467	
468	Reproducible Research Statement
469	Further details are available from Dr. Erez Shmueli (e-mail, shmueli@tau.ac.il).
470	Statistical code will be available after acceptance.

471	Supplementary Materials for:
472	Self-reported and physiological reactions to the third BNT162b2 mRNA
473	COVID-19 (booster) vaccine dose
474	Merav Mofaz, MSc ¹ , Matan Yechezkel, MSc ¹ , Grace Guan, MSc ² , Margaret L. Brandeau, PhD ² , Tal
475	Patalon, MD ³ , Sivan Gazit, MD ³ , Dan Yamin, PhD ^{1,4,+} , and Erez Shmueli, PhD ^{1,5,+,*}
476	¹ Department of Industrial Engineering, Tel Aviv University, Tel Aviv, Israel.
477	² Department of Management Science and Engineering, Stanford University, Stanford CA, USA.
478	³ Kahn Sagol Maccabi (KSM) Research & Innovation Center, Maccabi Healthcare Services, Tel Aviv,
479	Israel.
480	⁴ Center for Combatting Pandemics, Tel Aviv University, Tel Aviv, Israel.
481	⁵ MIT Media Lab, Cambridge MA, USA.
482	⁺ Equal contribution

483 *Corresponding author. Email: shmueli@tau.ac.il

484	Appendix	A: Self-re	ported qu	iestionnairs
-----	----------	------------	-----------	--------------

485

486 Enrollment questionnaire

- 487 All participants will fill a one-time enrollment questionnaire that includes demographic questions
- 488 and questions about the participant's health condition in general. Specifically, the questionnaire
- 489 will include the following: age, gender, height, weight and underlying medical conditions (Listed
- 490 in Table 1, main text). Other questions such as name, address, phone number and email will be
- 491 recorded and used by the survey company to contact the participants. The answers will be filled-
- in directly by the survey company to the study's secured dashboard.
- 493

494 Vaccination questionnaire

- 495 The vaccination questionnaire we will use includes the following question:
- 496 o COVID-19 vaccination date, time and dose number.
- 497

498 Daily questionnaire

All participants will complete the daily self-reported questionnaire in a dedicated application (the
PerMed mobile application). The daily questionnaire we will use includes the following
questions:


- 502 How is your mood today? Awful $(1) \cdot Bad (2) \cdot OK (3) \cdot Good (4) \cdot Excellent (5)$
- 503 How would you describe the level of your stress during the last day? Very Low (1) •
 504 Low (2) Medium (3) High (4) Very high (5)
- How would you define your last night sleep quality? Awful (1) Bad (2) OK (3) •
- 506 Good (4) Excellent (5)
- 507 o Try to remember how many minutes of sports activity you performed on the last day?

508	0	Have you experienced one or more of the following symptoms in the last 24 hours? • My
509		general feeling is good, and I have no symptoms \bullet Heat measured above 37.5 \bullet Cough \bullet
510		Sore throat • Runny nose • Headache • Shortness of breath • Muscle aches • Weakness /
511		fatigue • Diarrhea • Nausea / vomiting • Chills • Confusion • Loss of sense of taste / smell
512		• Other symptom.
513		

514 Appendix B: Additional Results

515 **Reported local and systemic reactions – stratification by age group**


- 516 We observe that the local and systemic reactions reported following the third dose were milder
- 517 for participants older than years compared to those younger than years (Figure S1).



519 Figure. S1. Local and systemic reactions reported by participants through the mobile 520 application stratified by age group. The bars represent the percentage of participants who 521 reported a given symptom. Error bars represent 90% confidence intervals.

522 Reported local and systemic reactions – stratification by gender

523 We observe that the local and systemic reactions reported following the third dose were milder in



524 males compared to females (Figure S2).

526 Figure. S2. Local and systemic reactions reported by participants through the mobile

527 **application stratified by gender.** The bars represent the percentage of participants who reported

a given symptom. Error bars represent 90% confidence intervals.

529 **Reported local and systemic reactions – stratification by underlying medical condition**

- 530 We observe that the local and systemic reactions reported following the third dose were milder
- 531 for participants with underlying medical conditions compared to those without (Figure S3).




Figure. S3. Local and systemic reactions reported by participants through the mobile
application stratified by underlying medical condition. The bars represent the percentage of
participants who reported a given symptom. Error bars represent 90% confidence intervals.

536 Changes in reported well-being indicators – stratification by age group

- 537 Changes in well-being observed during the first two days after the third vaccine dose were found
- to be higher for participants younger than years compared to those older than years, with
- the exception of reported stress level (Figure S4).





Figure S4. Changes in well-being indicators reported by participants through the mobile application stratified by age group. (A) mood level, measured on a 1-to-5 Likert scale. (B) Stress level, measured on a 1-to-5 Likert scale. (C) Sport duration, measured in minutes. (D) Sleep quality, measured on a 1-to-5 Likert scale. Changes in well-being indicators were calculated by subtracting the baseline values from the daily values. Error bars represent 90% confidence intervals. Horizontal dashed lines represent no change compared to baseline levels.

547 Changes in reported well-being indicators – stratification by gender

548 Changes in well-being observed during the first two days after the third vaccine dose were found



to be similar for males and females (Figure S5).

550

551 Figure S5. Changes in well-being indicators reported by participants through the mobile

application stratified by gender. (A) mood level, measured on a 1-to-5 Likert scale. (B) Stress

been level, measured on a 1-to-5 Likert scale. (C) Sport duration, measured in minutes. (D) Sleep

quality, measured on a 1-to-5 Likert scale. Changes in well-being indicators were calculated by

- subtracting the baseline values from the daily values. Error bars represent 90% confidence
- intervals. Horizontal dashed lines represent no change compared to baseline levels.

557 Changes in reported well-being indicators – stratification by underlying medical condition

- 558 Changes in well-being observed during the first two days after the third vaccine dose were found
- to be higher for participants without underlying medical conditions compared to those with
- underlying medical condition, with the exception of reported stress level (Figure S6).





Figure S6. Changes in well-being indicators reported by participants through the mobile application stratified by underlying medical conditions. (A) mood level, measured on a 1-to-5 Likert scale. (B) Stress level, measured on a 1-to-5 Likert scale. (C) Sport duration, measured in minutes. (D) Sleep quality, measured on a 1-to-5 Likert scale. Changes in well-being indicators were calculated by subtracting the baseline values from the daily values. Error bars represent 90% confidence intervals. Horizontal dashed lines represent no change compared to baseline levels.

568 Changes in physiological indicators – stratification by age group

- 569 Changes in physiological indicators after the third vaccine dose stratified by age group were
- 570 consistent with those observed in the general population (considerable changes during the first
- 571 two days after vaccine administration that faded nearly entirely after three days). These changes
- were found to be higher for participants younger than 50 years compared to those older than 50




573 years (Figure S7).

Figure S7. Changes in physiological indicators measured through the smartwatch stratified by age groups. Mean difference in heart rate and heart rate variability-based stress indicators following the third dose, recorded by a smartwatch, compared to their baseline levels: (A and B) heart rate, (C and D) heart rate variability-based stress. Mean values are depicted as solid lines; 90% confidence intervals are presented as shaded regions. The horizontal dashed line represents no change compared to the baseline levels, and vertical lines represent 24-hour periods.

580 Changes in physiological indicators – stratification by gender

- 581 Changes in physiological indicators after the third vaccine dose stratified by gender were
- 582 consistent with those observed in the general population (considerable changes during the first
- two days after vaccine administration that faded nearly entirely after three days). These changes



were found to be higher for females compared to males (Figure S8).

Figure S8. Changes in physiological indicators measured through the smartwatch stratified
by gender. Mean difference in heart rate and heart rate variability-based stress indicators
following the third dose, recorded by a smartwatch, compared to their baseline levels: (A and B)
heart rate, (C and D) heart rate variability-based stress. Mean values are depicted as solid lines;
90% confidence intervals are presented as shaded regions. The horizontal dashed line represents
no change compared to the baseline levels, and vertical lines represent 24-hour periods.

591 Changes in physiological indicators – stratification by underlying medical condition

- 592 Changes in physiological indicators after the third vaccine dose stratified by underlying medical
- 593 condition were consistent with those observed in the general population (considerable changes
- during the first two days after vaccine administration that faded nearly entirely after three days).
- 595 These changes were found to be higher for participants without underlying medical conditions
- 596 compared to those with underlying medical condition (Figure S9).




Figure S9. Changes in physiological indicators measured through the smartwatch stratified by underlying medical conditions. Mean difference in heart rate and heart rate variability-based stress indicators following the third dose, recorded by a smartwatch, compared to their baseline levels: (**A** and **B**) heart rate, (**C** and **D**) heart rate variability-based stress. Mean values are depicted as solid lines; 90% confidence intervals are presented as shaded regions. The horizontal dashed line represents no change compared to the baseline levels, and vertical lines represent 24hour periods.

604 14 days analysis for self-reported local and systemic reactions after the third dose

- 605 We observe a sharp decline in reported local and systemic reactions following three days after the
- third vaccination dose, and nearly a complete halt within 14 days post-vaccination (Figure S10).
- Fatigue and headache were the most frequent reactions reported and lasted longer than the other
- 608 reported reactions.




Figure S10. Most frequent local and systemic reactions reported by participants through the
mobile application after the third dose. (A) fatigue, (B) headache, (C) muscle pain, (D) fever,
and (E) chills. Error bars represent 90% confidence intervals.

613 Number of participants receiving each vaccine dose

- 614 1,503 participants reported receipt of at least one of the three BNT162b2 mRNA COVID-19
- 615 vaccine shots after joining the study. Specifically, out of these 1,503 participants serving as the
- base cohort for our analyses, 223 received during the study period their first dose, 351 their
- 617 second dose, and 1,231 their third dose (Table S1).

cipants receiving each vaccine dose Number of participants (n)
26
129
1,122
76
117
4
29

618